Vik is a Managing Director at Foresite Capital, evaluating and pursuing investments at the intersection of technology and life sciences, including in personalized and precision healthcare. He is also co-founder and CEO of Foresite Labs. Vik serves as Director & Interim President of Xaira Therapeutics (jointly incubated by Foresite Labs and ARCH Venture Partners), among several other companies in the Foresite Labs and Capital portfolios, and is a Non-Executive Director of Genomics England.
Prior to joining Foresite, Vik was the Chief Scientific Officer of GRAIL, a life sciences and healthcare company working to detect cancer early when it can be cured (acquired by ILMN), and a co-founder and Chief Scientific Officer of Verily, an Alphabet company, where he also served as chair of its Scientific Advisory Board. A former academic principal investigator, Vik is now an adjunct Associate Professor at the Stanford University School of Medicine. His academic research interests lie at the interface of the physical sciences, engineering, and the life sciences.
He holds a Ph.D. in physical chemistry from the Massachusetts Institute of Technology and a combined B.A./M.S. from the University of Pennsylvania. Vik’s scientific and engineering awards include the Anatole Abragam Prize (2012), the R&D 100 Award for the most promising commercialized technologies (2011 and 2013), and the Department of Energy’s LBL Innovation Grant (2013). In 2011, he was named as a Visiting Professor of the Chinese Academy of Sciences.
